Recombinant Human Serum Albumin/ALB Protein (HEK293)

Serum albumin, primarily produced by the liver, is the most abundant protein in human plasma and plays a crucial role in maintaining oncotic pressure, transporting various molecules, and acting as a reservoir for hormones and drugs. Research into recombinant human serum albumin (rHSA) has gained significant attention due to its potential therapeutic applications and advantages over traditional plasma-derived albumin. The production of rHSA offers a safer alternative, eliminating risks related to bloodborne pathogens, while also allowing for large-scale production and purification in controlled environments. Furthermore, rHSA can be engineered for enhanced stability and extended half-life, providing improved efficacy for drug delivery systems. Studies have demonstrated its use in various clinical settings, including liver disease, critical care, and as a carrier for therapeutics in cancer treatment. Recent advancements in biotechnology, such as genetic engineering and novel expression systems, have facilitated the development of rHSA with superior properties, leading to an increased interest in its application in medicine. Investigating the structure-function relationship of rHSA is essential for optimizing its performance and understanding its interaction with other biomolecules. As the demand for safer and more efficient therapeutics continues to rise, rHSA remains a pivotal focus in both academic and industrial research, promising to revolutionize treatment protocols and improve patient outcomes in the future.